NUS Engineering team develops novel technology to print customised tablets for personalised medicine

Food and Healthcare Press Releases Thursday May 26, 2016 11:17
SINGAPORE--26 May--PRNewswire/InfoQuest

A team of researchers from the National University of Singapore (NUS) have found a way to make personalised medicine cheaper and easier. Imagine if you could combine the myriad of pills you need to take for your ailment in just one tablet; or if you need only to take the medication once a day and the drug will be slowly released throughout the day at different rates to treat your illness; or if doctors could easily make tablets on the spot that are tailored to each patient's needs.

http://photos.prnasia.com/prnvar/20151130/8521508170LOGO

All these could become a reality with a new method of tablet fabrication designed by Assistant Professor Soh Siowling and PhD student Ms. Sun Yajuan from the Department of Chemical and Biomolecular Engineering at the NUS Faculty of Engineering. The novel system can make customisable pills that release drugs with any desired release profiles.

Customised tablets for optimal therapeutic results
Releasing drugs in a timely manner is important for optimal therapeutic effect in the human body. Different types of clinical circumstances may call for different types of timed release of drugs.

While there are some existing tablet-production methods, including 3D printing, that can allow certain flexibility, they have their limitations -- low dosage, release profiles that are non-continuous, or the drugs are released in a large burst in the initial stage, and poor durability of the tablet given its quick breakdown. These methods are also only able to fabricate tablets that release drugs with a limited type of profiles.

A fully customisable fabrication method

"For a long time, personalised tablet has been a mere concept as it was far too complex or expensive to be realised. This new tablet fabrication method is a game changer -- it is technically simple, relatively inexpensive and versatile. It can be applied at individualised settings where physicians could produce customised pills on the spot for patients, or in mass production settings by pharmaceutical companies," said Asst Prof Soh.

Instead of manufacturing the drug tablet by printing layer by layer, the drug tablet designed by the NUS team consists of three components, including a polymer containing the drug in a specifically designed shape that will determine the rate of release of the drug. By adjusting the shape of the drug-containing polymer, it is thus possible to release drugs at any desired rate.

Using the system designed by the NUS team, a doctor only needs to draw the desired release profile in a computer software to generate a template for making tablets specific to a patient's treatment, which can then be used to easily produce the desired pills using a 3D printer. The system is easy to use and does not involve any complex mathematical computation whenever a new release profile is needed. The fully customisable system is able to create a template to print tablets for any release profile.

The use of a commercially available 3D printer in this method also makes it a relatively cheap way of making personalised medicine a reality.

In drug delivery, it is also important to administer more than one type of drug into the human body simultaneously to treat an illness. This fabrication method can also be modified to include multiple types of drugs loaded within the same tablet -- and more importantly, each drug can be customised to release at different rates even within the same tablet.

For more information: http://news.nus.edu.sg/press-releases/10439-customised-tablets-personalised-medicine
Logo - http://photos.prnasia.com/prnh/20151130/8521508170LOGO

Latest Press Release

Medical Device Manufacturer Advant Medical Celebrates Its 25th Anniversary

Advant is a successful medical device manufacturer with corporate offices located in Galway, Ireland. For a quarter of a century, Advant has seen significant growth and development expanding into two locations in Ireland, Mexico and Costa Rica. With over...

Michel Orsinger Assumes Role as Chairman of Limacorporate#s Advisory Board

LimaCorporate is pleased to announce that Michel Orsinger, Board Member of LimaCorporate's Advisory Board, will assume the role of Chairman of the Board. Michel joined the Advisory Board mid-2017 following a long and successful global career in...

Merck and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxorubicin (PLD), a type of chemotherapy, compared with PLD did not meet the...

APEC#s Rare Disease Action Plan Sets Precedent to Integrate Rare Disease Care by 2025

- Asia-Pacific Economic Cooperation (APEC) Life Sciences Innovation Forum (LSIF) Rare Disease Network comprises Rare Disease International, Queensland University of Technology and Shire (representing as industry co-chair). - Aims to define, diagnose and...

Grunenthal Acquires Averitas Pharma and Establishes Commercial Footprint in the US

Grunenthal announced today that it has acquired the US-based pharmaceutical company Averitas Pharma, thereby extending its commercial footprint to the United States. Averitas Pharma will be commercialising the pain patch Qutenza(R) (8 % capsaicin) for...

Related Topics